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The p53 is a 53-kD nuclear phosphoprotein whose expression is associated
with cellular proliferation (1-3) . While the physiologic functions of p53 and its
role in malignancy are as yet unclear, evidence suggests that the gene product
can participate in the transforming event ; cotransfection experiments showed
thatp53 can complement the Ha-ras protooncogene in transformation of primary
rodent cells (4-6) . The p53 is expressed in a variety of leukemic cell lines and
the abnormal cells from patients with various hematologic malignancies (7-9) .
The normal counterparts of many of these transformed hematopoietic cells
express negligible levels ofp53 protein (7) . We have found that cells from several
lymphoid but not myeloid lines synthesize the p53 protein (7) . Lack ofexpression
of p53 can occur in cell lines with structural alterations of the p53 gene region,
as was shown for the human promyelocytic cell line HL-60 (10), murine lym-
phoma (11), and erythroleukemia (12) cell lines and human osteosarcoma cell
lines (13) .
Chronic myelogenous leukemia (CML)' displays a clonal population of cells
evolved from a transformed pluripotent hematopoietic stem cell (14). This clone
can be identified by the presence of a specific chromosomal translocation t(9 ;22)
(Philadelphia chromosome [Ph']) . After a clinically benign phase, characterized
by an increased number of immature myeloid precursors in the bone marrow
and peripheral blood, a terminal "blast crisis" phase develops that resembles
acute leukemia . In this phase, the blast cells appearing in bone marrow and
peripheral blood are predominantly myeloid (70% of cases) or lymphoid (30%
of cases) . In this study, we used CML cells as a model to examine expression of
p53 in two different cell lineages . Cell lines established from patients in either
myeloid or lymphoid blast crisis ofCML, and fresh cells fromCML patients were
screened for presence of p53 mRNA and protein, and experiments were per-
formed to study the differential expression ofp53 in these hematopoietic cells .
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Materials and Methods
Cell Lines.
￿
The following Ph'+ cell lines were examined for p53 expression: K562,
EM-2, EM-3, KCI-22 (myeloid lines, [15-17]) and BV173, NALM-1, MBL, SK-CML8-
Bt(9;22) (lymphoid lines, [ 18-21 ]). Furthermore, we studied somatic hybrids formed from
fusions of myeloid (p53 nonexpressor) and lymphoid (p53 expressor) parental lines; Dutko
and Putko are hybrids of K562 (myeloid, p53 mRNA nonexpressor) and PUT or Daudi
(lymphoid expressors), respectively (22, 23). HP-1 is a hybrid of HL-60 (promyelocyte
with a deletion and non-expression of p53) and PUT (24). Also, we examined p53
expression in EBV-immortalized, Ph' - SK-CML8-BN lymphocytes (21), which are from
the same individual as Ph'+ SK-CML8-Bt(9;22) lymphocytes (generous gifts of B. Clarkson,
Memorial Sloan Kettering, NY). In addition, the promyelocytic cell line HL-60 (25),
myeloblastic KG-1 (27), Burkitt's lymphoma lines Daudi and PUT (22, 26), and human
T lymphotropic virus (HTLV-I) immortalized T-lymphocytec S-LBI (28) were tested.
Cells were grown in a medium (Flow Laboratories, Inc., McLean, VA) enriched with 10%
FCS in a 7.5% COs humidified atmosphere.
Patients.
￿
After receiving informed consent from the patients with CML, heparinized
venous blood was drawn and subjected to Ficoll density gradient separation (29). The
differential count of the nonadherent, mononuclear fraction was determined by morpho-
logical inspection of Giemsa-stained cytospin preparations: myeloid cells comprised be-
tween 94 and 96% of the leukocytes. Diagnosis and staging of the patients was performed
by using clinical, morphological, cytogenetic, and immunohistochemical criteria including
examination for terminal deoxynucleotidyl transferase (TdT) and expression of the
common ALL antigen (14).
Antibody.
￿
p53 mAb (PAb421) was affinity purified and concentrated from the super-
natant of an established hybridoma cell line (generous gift of E. Harlow, Cold Spring
Harbor, NY) (30) by (NH4)$SO4 precipitation and binding to Sepharose-protein A
columns (Sigma Chemical Co., St. Louis, MO) (31).
Recombinant DNA Constructs. The following p53 clones were used as probes: the
complete insert of the cDNA clone pR4-2 (32) (complementary to exons II-XI); the 350-
bp Bam HI-Xba I fragment of the clone pBT53 (p53 promoter and part of exon I) (33).
For detection ofp53 mRNA, the 480-bp Nco I-Nco I fragment ofpR4-2 (complementary
to exons II-V) was used. For the transfection experiments we used the plasmid constructs
pBXB53 and pRXB53, containing 350 by and 2.4 kb, respectively; ofthe 5'p53 sequences
with promoter activity (33). The pSV2-CAT containing the SV40 early promoter was
used to determine transfection efficiency and chloramphenicol acetyltransferase (CAT)
enzyme stability (34); pSVO-CAT (lacking promoter sequences) was used as a negative
control (34). The 414-bp Pst I/Pst I fragment detecting exon II of the c-myc gene (35)
was generated from the plasmid pHSRI and used to probe for c-myc mRNA.
p53 Protein Synthesis.
￿
Cells (5 x 106) were washed several times with PBS, resuspended
(1 ml) in methionine-free a medium with 10% FCS and 200,Ci [86S]methionine (Amer-
sham Corp., Arlington Heights, IL) or [62P,]orthophosphate (500 uCi). After a 5-h
incubation, the cells were washed several times and lysed as described previously (7) . The
cell lysate was precleared by absorption on Staphylococcus aureus and nonimmune serum.
Equal amounts of labeled protein were then precipitated with mAb PAWL SDS-PAGE
was performed according to Laemmli (36). Precipitated proteins were visualized by
autoradiography.
Inhibition of New Protein Synthesis.
￿
K562 cells were seeded at 4 x 105 cells/ml in a
medium with 10% FCS 4 h before treatment with the protein synthesis inhibitor cyclo-
heximide (CHX) (Sigma Chemical Co.). At 0 h, CHX was added to the culture medium
to a final concentration of 20 ug/ml. After 3 h the cells were washed two times in PBS
and RNA was extracted.
DNA and RNA Isolations.
￿
Extraction of genomic DNA from cell lines was performed
by lysing the cells with 3 % NP-40 and digesting the nuclei for 16 h at 50° C with proteinase
K (Bethesda Research Laboratories, Bethesda, MD) (37). The DNA was precipitated by
adjustment of the solution to a final concentration of 2 M ammonium acetate andLLJBBERT ET AL.
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subsequent addition of 1 vol isopropanol, followed by several rinses in 2 M ammonium
acetate/80% ethanol, and 80% ethanol, as described by Hardy et al. (38).
Total cellular RNA was extracted from cell lines and fresh human hematopoietic cells
by the hotphenol method (37). Briefly, cellswere lysed at 60° C in guanidine isothiocyanate
(Eastman Kodak Co., Rochester,NY) and extracted into phenol-chloroform. Afterseveral
extractions the solution was precipitated with 2 vol ethanol. The precipitate was redis-
solved and digested with proteinase K for 2 h at 37'C. After several subsequentextractions
in phenol-chloroform and chloroform, the aqueous phase was again precipitated with 2
vol ethanol .
Southern and Northern Blot Analyses.
￿
Restriction endonuclease digestions of genomic
DNA were performed following manufacturer specifications. For methylation studies, 5-
10X excess of Hpa 11 and Hha I (Boehringer Mannheim Biochemicals, Indianapolis, IN)
was used for digestion, and plasmid DNA was added to aliquots of the reaction mix to
monitor completeness of digestion. DNA was size fractionated on Tris-acetate or tris-
borate agarose gels. Total RNA was size fractionated on denaturing formaldehyde gels as
described (37). Nucleic acids were transferred to nylon-based filters (NCI; Biodyne, Irvine,
CA). Hybridization with GYP-oligolabeled (39) p53-specific probes was carried out as
described (37); filters were rinsed to a final stringency of 0.25X SSC (DNA filters) or 0.1 X
SSC (RNA filters) at 65°C for 15 min (1X SSC: 0.15 mol/liter NaCl; 0.015 mol/liter
trisodium citrate).
DNA Transfection and CATAssay.
￿
The BV173 lymphoid and K562 myeloid cell lines
were transfected by a modification of the DEAE-dextran method (40). Briefly, 10' cells
were washed four times with serum-free medium and incubated for 4.5 h in 10 ml serum-
free medium with 0.25 mg/ml DEAE-Dextran (Sigma Chemical Co.), 0.1 M Tris (pH
7.3), 10-4 M chloroquin (Sigma Chemical Co.), and 10 Wg of plasmid DNA. The cells
were washed and incubated in a medium with 10% FCS for 42 h, then lysed by freeze-
thawing, and cell extract was used to acetylate ['4Clchloramphenicol (Amersham Corp.).
Labeled chloramphenicol and its acetylated forms were separated by ascending silica gel
thin layer chromatography (TLC) (with solvent chloroform/methanol 95 :5) and visualized
by autoradiography.
Results
Expression ofp53 mRNA and Protein in CML Cell Lines and Cells from Patients
with CML. A number of leukemic cell lines established from patients with CML
were screened by Northern blot analysis for expression of p53 mRNA (Fig. 1 A,
Table 1). T-lymphocytic S-LB1, immortalized by infection with HTLV-1, was
used as a positive control and the HL-60 myeloid cell line (with a deletion of the
p53 gene) served as negative control. The p53 mRNA was detected in all the
lymphoid lines, which includes SK-CML8-Bt(9;22), MBL, BV 173, SK-CML8-BN
and S-LB 1 (Fig. 1 A, lanes 1-3, 8, and 10), and EM-2 and EM-3 myeloid lines
(lanes 5 and 6). Negligible p53 mRNA was detectable in the myeloid CML cell
lines K562 and KCI-22 (lanes 4 and 7). The p53 mRNA was not detected in
K562 cells even after treatment of the cells with an inhibitor of protein synthesis
(cycloheximide) (data not shown). The filter was rehybridized with c-myc (Fig.
I B). HL-60 cells expressed the largest amounts of c-myc mRNA, followed by
EM-2, EM-3 (Fig. 1B, lanes 7-9), KCI-22, and K562 . Small to undetectable
amounts of c-myc mRNA were found in the lymphoid lines.
We studied the ability of the CML cell lines to synthesize p53 protein by
metabolic labeling and immunoprecipitation, using the mAb PAb421 (Fig. 2).
The p53 protein was detected in the lymphoid cell lines BV 173, NALM-1, MBL
(lanes 4-6). No p53 protein was detected in the myeloid lines including K562,
EM-2, EM-3 (lanes 7-9), and KCI-22 (data not shown). Of note, in lane 6 (MBL),876
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FIGURE 1 . (A) p53 mRNA
accumulation in myeloid and
lymphoid CML cell lines. To-
tal RNA(20 jig per lane) from
SK-CML8-Bt(9 ;22) (lymph-
oid, CML, lane 1), MBL
(lymphoid, CML, lane 2),
BV173 (lymphoid, CML, lane
3), K562 (myeloid, CML, lane
4), EM-2 (myeloid, CML, lane
5), EM-3 (myeloid, CML, lane
6), KCI-22 (myeloid, CML,
lane 7), SK-CML8-BN (lane
8),HL-60 (lane 9),S-LB 1 (lane
10) was electrophoresed, blot-
ted, and hybridized with the
480-bp NcoI-Nco Ifragment
of the oligolabeled (39) p53
cDNA clone pR4-2 (32). The
filter was then washed andau-
toradiographed for 4 d . The
28S and 18S bands of rRNA
served as molecular weight
markers . (B) The same filter
was rehybridized with the
414-bp Pst I-Pst I fragment
(exon 2) of the human c-myc
clone pHSRI (35) .
TABLE I
Expression ofp53 and c-myc in Cells ofLeukemic Lines, Summarizing Figs. 1-3, 5, and 6
The characteristics or the cell lines are provided in their corresponding references . Abbreviations :
NT, not tested ; ±, only trace amounts detectable .
a 70-kD band is quite prominent . We noted this band to coprecipitate with p53
in five separate experiments ; it is the correct molecular weight to be the major
heat shock protein Hsp70 . Prior studies have shown that the p53 protein can
complex with this protein (41) .
p53 expression was also studied in two EBV-immortalized B lymphocyte lines
that differ in the presence [SK-CML8-Bt(9 ;22)] or absence (SK-CML8-BN) of
the Ph' chromosome . Both were established from a 63 yr old male patient with
CML in the chronic phase (21) . The SK-CML8-Bt(9;22) line represents the
Cell line Refer-
ence Characteristics Ph' p53
mRNA
p53
protein
c-myc
mRNA
HL-60 25 Myeloid - - - +
K562 15 Myeloid + - - +
KCL:22 17 Myeloid + ± - +
EM-2 16 Myeloid + + - +
EM-3 16 Myeloid + + - +
Putko 22 Hybrid + + + NT
Dutko 23 Hybrid + + + NT
BV173 18 Lymphoid + + + t
MBL 20 Lymphoid + + + -
SK-CML8-Bt(9;22) 21 Lymphoid + + + -
SK-CML8-BN 21 Lymphoid - + + ±
S-LB1 28 Lymphoid - + + -LOBBERT ET AL .
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FIGURE 2 . p53 protein syn-
thesis in myeloid and lymph-
oid CML cell lines . 5 X 106
cells from HL-60 (lane 2), S-
LB1 (lane 3), BV 173 (lane 4),
NALM-1 (lane 5), MBL (lane
6), K562 (lane 7), EM-2 (lane
8),EM-3 (lane 9), were labeled
metabolically with ["S)methi-
onine for 5 h, then immuno-
precipitated with PAb421
(30), electrophoresed on a
SDS/PAGE and autoradi-
ographed . (Lane 1) Molecular
weight markers (M, X 10- ') .
The ^-43 kD band in lanes3-
10 probably represents actin,
which can polymerize during
immunoprecipitation . The
-70-kD band visible in lane 6
may represent the major heat
shock protein Hsp 70.
FIGURE 3 .
￿
Synthesis of phosphorylated p53 protein in Ph" and
Ph` B lymphocyte lines from the same patient. 5 X 106 cells were
labeled metabolically with ["P,]orthophosphate for 5 h . Ph" SK-
CML8-Bt(9;22) (lane 1) and Ph`- SK-CML8-BN (lane 2) cells were
immunoprecipitated with PAb 421 ; SK-CML8-Bt(9;22) was also
precipitated with calf serum (lane 3) ; each immunoprecipitate was
size fractionated by SDS/PAGE and autoradiographed . The -43-
kD band visible in lanes 1 and 2 probably represents polymerized
actin .
malignant clone of the disease, while SK-CML8-BN was immortalized from the
untransformed, normal B lymphocyte population . Northern blot analysis showed
presence ofp53mRNA in both cell lines (Fig . 1, lanes 1 and 8) . Using metabolic
labeling with [s1p1]orthophosphate, we also detected synthesis of a phosphoryl-
ated p53 protein in both of these lines (Fig . 3, lanes 1, 2) .
We also performed Northern blot analysis of p53 expression in fresh CML
cells from three patients in myeloid blast crisis and one patient in the chronic
phase of Ph" CML (Table 11) . We found that p53 mRNA was expressed in
myeloid cells from two patients in myeloid blast crisis and one patient in chronic
phase, while no p53 mRNA could be detected in cells from patient 4 (Fig . 4,
lanes 1-4) . The amounts ofmRNA expressed were comparable to that detected
in the T-lymphocyte line S-LB1 (lane S) . HL-60 cells expressed no p53 mRNA
(lane H).
Analysis of Expression ofp53 mRNA in Ph" Somatic Hybrids and Their Parental
Lines. Somatic hybrids (Dutko, Putko) formed between K562 (myeloid, p53
mRNA nonexpressor) and one oftwo lymphoid lines (Daudi, PUT ; p53 expres-878
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See Fig . 4 as well .
TABLE II
Expression ofp53mRNA in Leukemic Cellsfrom Patients with CML
FIGURE 4 . p53 mRNA ac-
cumulation in leukemic cells
from patients (Pt.) with CML.
Total RNA (20 ug per lane)
from Pt. 1, CML myeloid blast
crisis (lane 1), Pt. 2, CML
chronic phase (lane 2), Pt . 3,
CML myeloid blast crisis (lane
3), Pt . 4, CML myeloid blast
crisis (lane 4), HL-60 (lane H),
S-LB 1 (lane S) was electropho-
resed, transferred, and hy-
bridized with theNco I-Nco I
fragment of the p53 cDNA
clone pR4-2 .
FIGURE 5 . p53 mRNA accumulation in so-
matic hybrids between myeloid and lymphoid
cells. Total RNA (20 fag per lane) from Putko
(lane 1), PUT (lane 2), K562 (lane 3), Dutko
(lane 4), Daudi (lane 5), HP-1 (lane 6), KG-1
(lane 7), HL-60 (lane 8), S-LB1 (lane 9) was
electrophoresed, blotted and hybridized with
the Nco I-Nco I fragment of the p53 cDNA
clonepR4-2 .
sors) were used to study the mechanisms governing expression of p53 mRNA .
In addition, we studied expression in a somatic hybrid (HP-1) between HL-60
(myeloid nonexpressor with loss of one and grossly rearranged remaining p53
allele) and PUT. The p53 mRNA was present in the lymphoid parental cells,
PUT and Daudi (Fig. 5, lanes 2 and 5; respectively), but not in the myeloid
parental cells K562 and HL-60 (lanes 3and8). Thep53 transcripts were present
in the three hybrid lines (Putko, lane 1 ; Dutko, lane 4; HP-1, lane 6) .
Analysis ofp53 protein synthesis in these lines and somatic hybrids by means
of metabolic labeling and immunoprecipitation showed that all lines that ex-
pressed p53 mRNA also expressed p53 protein (Fig . 6) . Southern blot analysis
of these cell lines using Eco RI digestion and probes detecting the 3' and 5'
regions of the gene showed that the 3' region of p53 was grossly intact, except
Number
Patient
Name
Sex Age Phase ofCML Ph'
p53
mRNA
detected
1 RH M 76 Myeloid blast crisis + +
2 BH F 15 Chronic + +
3 EL M 35 Myeloid blast crisis + +
4 MR M 49 Myeloid blast crisis + -LUBBERT ET AL .
￿
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FIGURE 6 . p53 protein synthesis in somatic hybrids be-
tween myeloid and lymphoid cells . (A) fs'S]methionine-la-
beled cells from Putko (lane 1), PUT(lane 2), K562 (lane 3),
HP-1 (lane 4), HL-60 (lane 5) were analyzed by SDS/PAGE.
(B)Same analysis with Daudi (lane 1), Dutko (lane 2), HL-60
(lane 3), K562 (lane 4), HP-1 (lane 5). The band at -43 kD
probably represents actin, which can polymerize during im-
munoprecipitation .
FIGURE 7.
￿
Structure of the p53 gene in p53 ex-
pressing and nonexpressing myeloidandlymphoid
cells . Eco RI-digested DNA (10wg per lane)from
HL60 (lane 1), HP-1 (lane 2), Daudi (lane 3), Dutko
(lane 4), K562 (lane 5), PUT (lane 6), Putko (lane
7) was electrophoresed, blotted, and hybridized
with the oligo-labeled p53cDNA pR4-2 . The filter
was then washed, and autoradiography was per-
formed.
for the p53 deletion found in both HL-60, as described previously (10), and HP-
1 (somatic hybrid of HL-60 and PUT) . Both showed a truncated 2.3-kb Eco RI
fragment (Fig. 7) . The somatic hybrid HP-1 also retained the normal p53 alleles
from thePUT parental line as demonstrated by the the presence of the normal
16-kb Eco RI band . The 5' region of all lines appeared grossly intact (data not
shown) .
Activation of the p53 Promoter Linked to an Indicator Gene (CAT) in Both a p53
mRNA Expressorand NonexpressorLine. Gene expression can be either positively
or negatively regulated by the interaction of nuclear proteins with promoter
sequences (42, 43) . We sought to study whether a difference could be detected
in the ability of K562 (myeloid p53 nonexpressor) and BV173 (lymphoid p53
expressor) to activate the p53 promoter. To this end, two plasmid constructs
(p53BXB and p53RXB) carrying p53 promoter sequences cloned in front of the
CAT gene (33) were transfected into each cell type . Activation of the promoter
was determined by assaying for CAT activity . The results are shown in Fig . 8.
Both p53/CAT constructs showed equal activity in each of the two cell lines880
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FIGURE 8 .
￿
Activity of the p53 promoter in p53 ex-
pressing and nonexpressing cells . (A) K562 cells were
transfected with pSV2-CAT (lane 1), p53BXB (lane
2), p53RXB (lane 3), pSVO-CAT (lane 4) and ana-
lyzed for CAT activity . The cells were lysed 48hafter
transfection, andthe cell extract was used to acetylate
("C]chloramphenicol. Silica gel thin-layer chromatog-
raphy was performed and the silica gel plate was
autoradiographed . (B) BV173 cells were transfected
with pSV2-CAT (lane 1), p53BXB (lane 2), p53RXB
(lane 3), pSVO-CAT (lane 4) and assayed for CAT
activity. CM, chloramphenicol; 3CM, 3-acetyl-chlor-
amphenicol .
(p53BXB and p53RXB in BV 173 : panel A, lanes 2 and 3, respectively ; p53BXB
and p53RXB in K562 ; panel B, lanes 2 and 3, respectively) . No significant
difference between the strength of the two p53/CAT constructs was observed .
An overall stronger CAT enzyme activity in BV 173 than K562 was observed in
repeated experiments and is most clearly reflected by the signal strength with
pSV2-CAT (lane 1 of panels A and B) .
DNA Methylation Pattern in a p53 mRNA Expressor and Nonexpressor Cell
Line . The pattern of demethylated CpG dinucleotides was studied in the p53
gene of BV173 (p53 expressor, CML lymphoid line) and in K562 (p53 mRNA
nonexpressor, CML myeloid line) . The DNA from both lines was digested with
the methylcytosine-sensitive restriction enzymes Hpa II (recognition site CCGG)
and Hha I (recognition site GCGC) and with the methylcytosine-insensitive
enzyme Msp I (isoschizomer of Hpa 11, recognition sites CmCGG and CCGG) .
Hybridization of a Southern blot containing these DNAs with the 3'-specific
probe pR4-2 yielded a band >23 kb that was identical in size for both lines in
Hpa II and Hha I digests (Fig . 9, lanes 1-4). Msp I digests yielded a number of
small bands of identical size in both cell lines (Fig . 9, lanes 5 and 6) . When
studying the 5' portion of the gene using the clone pBT53 as probe, we detected
a band of ^-700 by in K562, BV173, and S-LB1 cells after digestion with either
Hpa II or Msp I (Fig . 10, lanes 1-6) (inspection of the ethidium bromide-stained
gel showed that in lane 6, less material was run, resulting in the faint 700-bp
band in that lane) . Digesting the DNA ofBV173, K562, and S-LB 1 with Hha 1
and probing the resulting Southern blot with pBT53, we found one band of
^ "670 by in each of the digests (Fig. 10, lanes 7-9) . This finding indicates the
presence of four demethylated CpG sites . The orientation of the fragments and
the position of the restriction sites flanking them were deduced from the
published sequence (33) and from double restriction enzyme digestions . The
700-bp Hpa II/Msp I band was diminished in size with Bam HI but not Xba 1,
and double digestion with Hha I and Xba I yielded a smaller fragment of 325LCBBERT ET AL .
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FIGURE 9 .
￿
DNA methylation of
the p53 gene (exons 2-11) in p53-
expressing (BV173) and nonex-
pressing (K562) cells. DNA was
digested with methylcytosine-sen-
sitive and -insensitive restriction
enzymes : K562 with Hpa II (lane
1), BV173 with Hpa 11 (lane 2),
K562 with Hha I (lane 3), BV173
with Hha I (lane 4), K562 with
Msp I (lane 5), BV173 with Msp I
(lane 6), then electrophoresed (10
rig per lane), transferred, and hy-
bridized to the p53 cDNA pR4-2 .
Molecular weight markers : Hind
III-digested A phage (left), Hae
III-digested OX 174 RF DNA
(right).
FIGURE 10 . DNA methyla-
tion of the p53 gene (pro-
moter region and exon 1) in
p53 expressing (BV 173, S-
LB1) and nonexpressing
(K562) cells . DNA was di-
gested : S-LB1 with Hpa II
(lane 1), K562 with Hpa II
(lane 2), BV173 with Hpa II
(lane 3), S-LB1 with Msp I
(lane 4), K562 with Msp I (lane
5),BV173 with Msp I (lane 6),
S-LB1 with Hha I (lane 7),
K562 with Hha I (lane 8),
BV 173 with Hha I (lane 9),
then electrophoresed (10 Ag
per lane), transferred, and hy-
bridized to the Bam HI-Xba
I fragment of the p53 clone
pBT53 . The size marks rep-
resent two fragments of $X
174 RF digested with Hae III .
FIGURE 11 .
￿
Distribution of de-
methylation sites in the p53
gene. (Open circles) demethylated
CCGG sites ; (open triangles) de-
methylated GCGC sites; (R) Eco
RI restriction sites ; (B) Bam HI
restriction site ; (X) Xba I restric-
tion site ; (inverted solid triangle)
cap site [position 312 in (33)] . Po-
sitions of sites are given relative
to the cap site .
by (data not shown) . Three of the demethylated sites map to a sequence in the
promoter region starting -730 by upstream of the hypothetical cap site ; the
fourth site of demethylation is located 85 by downstream of the cap site (Fig.
11). The methylation status of theCCGG site 155 by downstream of the cap site882
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could not be determined because the fragment size of 180 by was below our
detection limit on Southern blot . Also, we did not evaluate other sites of
demethylation upstream of the CCGG sequence at approximately -730 of the
cap site .
Discussion
Prior studies by others (8, 9) as well as ourselves (7) have found that cells of
lymphoid origin can express high levels ofp53 protein, whereas cells of myeloid
origin express negligible amounts of p53 . In the present study we investigated
thep53 expression usingCML cells as a model . This malignancy originates from
a single pluripotent hematopoietic stem cell that can differentiate into either
lymphoid or myeloid cells.We found that all lymphoidCML lines expressed p53
mRNA and protein. None of the myeloid linesexpressed detectable p53 protein ;
and negligible levels ofp53 mRNA were found in two myeloid CML lines K562
andKCI-22, even aftertreatmentofK562 cells withCHX, an inhibitorof protein
synthesis . Accumulation ofmRNA coding for other transiently expressed onco-
genes and growth factors is increased when the cells are exposed to an inhibitor
of protein synthesis (44, 45). Surprisingly, however, two myeloidCML lines (EM-
2, EM-3) and primary leukemic cells from three of four patients with CML
expressed p53 mRNA . Our present results, taken together with our prior
findings, suggest that two groups of myeloid leukemic lines can be found with
respect to expression of p53 : those that express negligible p53 mRNA and
protein (e.g ., K562, KCI-22, KG-1, ML-3, U937, A7) and those that accumulate
p53 transcripts but no protein (EM-2, EM-3). Possibly, cells belonging to the
latter group synthesizean antigenically altered p53 protein that is notrecognized
by the PAb421 mAb. This phenomenon has been described in HeLa cells (46) .
The appearance of p53 in myeloid cells might mean that expression of the gene
is not regulated normally inCML.
To study the regulatory mechanisms responsible for p53 expression, we
examined two somatic hybrid lines that were the fusion products of K562
(myeloid, p53 RNA nonexpressor) and either of two lymphoid lines (p53 ex-
pressors) . Our results indicate that p53 expression is a dominant feature, with
the somatic hybrids expressing both p53 mRNA and protein . This suggests that
lack ofp53 expression in K562 is probably not the result of an inhibitory trans-
acting protein .
We also studied the ability of the p53 mRNA expressor and nonexpressor
CML linesto activate the p53 promoter attached to the CAT gene . Two plasmid
constructs containing 350 by and 2.4 kb of the 5' p53 region (part of exon 1
and 5' flanking sequences, both shown to contain the p53 promoter [33]) were
transfected into K562 (myeloid, p53 nonexpressor) andBV173 (lymphoid, p53
expressor) . We found that both of these constructs were about equally active in
BV173 and K562, indicating that the lack of p53 expression by K562 was not
because of either the lack of a positive or presence of a negative trans-activator
ofp53.
The distribution pattern of demethylated CpG dinucleotides is a feature of
genes that is correlated with their expression (47, 48) . In DNA of vertebrates,
cytosine is methylated up to 90% of the time, and this modification is almostLLTBBERT ET AL .
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always found in the sequence mCpG . Demethylation of this sequence at certain
sites in the gene may be necessary for gene expression ; and for a number of
tissues, this demethylation occurs in genes actively expressed, whereas the same
sites are methylated in nonexpressing tissues (47) . For many genes, however, no
differences in the methylation pattern between expressing and nonexpressing
tissues have been detected . Of these, so-called "housekeeping genes" (genes
expressed in a variety of tissues often at a variety of stages of differentiation)
have a specific distribution pattern of methylated and demethylated cytosine/
guanine dinucleotides (CpGs) (48) . Sites of demethylation are clustered in a CpG-
rich 5' region of an otherwise hypermethylated and CpG-poor gene (48, 49) .
These clusters have been termed Hpa 11 Tiny Fragments (HTF) islands (49) .
Our analysis showed no difference in the methylation pattern ofBV 173 (lymph-
oid, p53 expressor) and K562 (myeloid, p53 nonexpressor) . Furthermore, we
found that the p53 gene is highly methylated over its entire coding region but
demethylated at least in four sites in and 5' of the noncoding first exon . This
pattern of hypomethylation is reminiscent of a HTF island in a housekeeping
gene . We have found the same pattern of methylation in another system of
differential p53 expression, quiescent (p53 mRNA nonexpressor) and actively
proliferating peripheral blood T lymphocytes (p53 expressor) (manuscript in
perparation) .
Based on the notion that p53 and c-myc may have similar functions, and the
observation that HL-60 cells lack p53 expression but exhibit c-myc amplification,
Wolfand Rotter (10) speculated that lack ofp53 expression may be compensated
by overexpression of c-myc. Our results are consistent with this notion . All
myeloid lines lacking p53 protein synthesis (as detected by PAb421) strongly
express c-myc mRNA, while all lymphoid lines express p53 protein but negligible
amounts of c-mycmRNA . Cells of none of the lines lack expression of both p53
and c-myc (see Table 1) .
Summary
Thep53 is a nuclear protein that is associated with normal cellular proliferation
and can cooperate with Ha-ras in causing cellular transformation in vitro . Lineage
association is known to existbetween p53 expression and normal lymphopoiesis,
but not myelopoiesis . We studied the expression ofp53 using chronic myelogen-
ous leukemia (CML) cell lines, somatic hybrids of these cells, and leukemic cells
from CML patients . Lymphoid CML lines expressed both p53 mRNA and
protein . We also analyzed p53 synthesis by two B-lymphoid lines from the same
CML patient ; cells of one line were derived from the neoplastic clone, cells of
the other were derived from the normal clone . Both synthesized equal amounts
of a phosphorylated p53 protein . None of the myeloid CML lines expressed
detectable p53 protein and two of four expressed negligible p53 mRNA . Two
other myeloid CML lines and myeloid cells from three of four patients expressed
p53 mRNA . These findings suggest that expression of the gene is not regulated
normally in CML . Several approaches were pursued to explore the differential
expression ofp53 . Southern blot analyses showed no gross alterations in the p53
gene from cells of either the expressing or the nonexpressing lines . No difference
in the pattern of demethylated CpG sites was noted in the region of the p53
gene in cells from K562 (myeloid p53 nonexpressor) and in BV 173 (lymphoid884
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p53 expressor). The sites of demethylation clustered in and around the p53
promoter in both cell lines. Somatic hybrids formed between a p53 mRNA
nonexpressor myeloid line (K562) and the parental p53 expressor lymphoid lines
(Daudi, PUT) produced p53 mRNA and protein, suggesting that p53 is a
dominantly expressed protein and that lack of expression in myeloid cells is not
mediated by a trans-acting negative regulatory protein. DNA transfection exper-
iments performed using the indicator gene chloramphenicol acetyltransferase
attached to promoter sequences ofp53 showed that these constructs were equally
activated in BV173 (p53 expressor) and K562 (p53 mRNA nonexpressor). The
mechanism ofp53 regulation in CML remains unclear.
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